|
Medications Research Grants Branch (MRGB)
Mission: To support the clinical development of new medications, or new indications for marketed medications, for the treatment of substance related disorders and/or nicotine dependence. The Branch places special emphasis on pharmacotherapy research to meet the needs of special populations, such as minorities, children, and women.
The MRGB plans and supports extramural research grants to test medications for the treatment of drug abuse and dependence disorders in several key areas: controlled compound assessment clinical pharmacology studies, controlled clinical trials for new treatment agents or new indications for marketed medications and clinical studies of the pharmacological effects and interactions among experimental addiction medications and medications for associated medical conditions and psychotherapeutic agents. The Branch also supports experimental pharmacotherapy studies to enhance the efficacy of approved marketed medications, and experimental pharmacotherapy studies of psychotropic or other medications used in the treatment of mental disorders in drug dependent individuals including drug-induced or drug-related mental disorders. MRGB staff members provide technical assistance to grantees, contractors, and applicants. The MRGB provides guidance is given to investigators and manages the administrative aspects of DPMCDA's research and development contract portfolio.
Medications Research Grants Branch Staff Contacts
Jamie Biswas, Ph.D. Chief
301-443-8096
jb168r@nih.gov
Manages the overall activities of the Branch. Coordinates activities involved in the planning and supporting of extramural research grants to test medications for the treatment of drug abuse and dependence disorders, including controlled clinical trials for new treatment agents or new indications for marketed medications. Contact for the MRGB Immunotherapy Program. DPMCDA representative for the NIDA Research Training Committee. Previous experience includes research in academia, and pilot plant chemistry and drug development in industry. Joined NIDA in 1991.
Ivan D. Montoya, M.P.H., M.D. Medical Officer
301-443-8639
imontoya@nih.gov
Clinical Director, Pharmacotherapies and Medical Consequences Grants. Program Official for grants testing medications-based therapies for cannabis, cocaine, opiates, and nicotine dependence. Medical Safety Officer assigned to project teams in DPMCDA. Supports the Data and Safety Monitoring Board of the DMPCDA. Clinical investigator in the DPMCDA and IRP. Member of several scientific interest workgroups. Previous experience includes seven years as a clinical investigator in the Intramural Research Program of NIDA, and four years in academia. Joined NIDA in December 1999.
Steve Oversby, R.N.
, Psy.D.
Health Scientist Administrator/Psychologist
301-435-0762
SOversby@Mail.NIH.Gov
PHS Officer and Program Official for clinical trial grants which involve safety and efficacy testing of medications for the treatment of opiate, cocaine, methamphetamine and club drug Substance Related Disorders (SRDs), as well as treatments for SRDs in vulnerable populations. Contact for the MRGB Methamphetamine Program. Member of several NIDA committees including African American Initiative, APA (Early Career Investigators), Social Neuroscience and EDQAC. Member of professional organizations including NAADAC, International Society of Addictions Nurses, and International College of Prescribing Psychologists. Past experience includes PHS Officer with NIMH, DC Dept. Mental Hlth and NIDA CCTN. Joined NIDA May 2002.
Medications Research Grants Branch (MRGB)
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Boulevard
Room 4123, MSC 9551
Bethesda, Maryland 20892-9551
(301) 443-1428
(301) 443-2599 (fax)
|
|
DPMCDA Index
About NIDA Contents
|
|
